Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and survival times. Appl Stat 2006;55:31-39.
Cited by
Items 901–1,000 of 1,000
Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines
Badger, S., McVeigh, J., & Indraratna, P. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00328-3 · Cited by 14
“These recommendations are primarily based on the EMPEROR-Preserved, TOPCAT, CHARM, and PARAGON-HF trials [49–52].”
MethodPost-Capillary Pulmonary Hypertension: Clinical Review
Riley, J. M., Fradin, J. J., Russ, D. H., Warner, E. D., Brailovsky, Y., & Rajapreyar, I. N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020625 · Cited by 13
“There is a paucity of evidence suggesting that specific drugs or regimens significantly decrease mortality and morbidity in patients with HFpEF [48–52].”
BackgroundBlood pressure and heart failure: focused on treatment
Chun, K., & Kang, S. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00271-y · Cited by 16
Contemporary treatment options in heart failure with preserved ejection fraction
Peikert, A., & Solomon, S. D. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae201 · Cited by 15
Self-citationdeFilippi, C. R., Shah, P. M., Shah, S. J., Alemayehu, W. G., Lam, C. S. P., Butler, J., Roessig, L., O’Connor, C. M., Westerhout, C. M., Armstrong, P. W., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011792 · Cited by 14
Self-citationFurukawa, N., Matsui, H., Sunaga, H., Nagata, K., Hirayama, M., Obinata, H., Yokoyama, T., Ohno, K., Kurabayashi, M., & Koitabashi, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-75757-8 · Cited by 14
“Recent studies showed alteration in the phosphorylation level of titin in HFpEF patients 5,28,29 .”
BackgroundMethodInfluentialIanoș, R., Iancu, M., Pop, C., Lucaciu, R. L., Hangan, A. C., Răhăian, R., Cozma, A., Negrean, V., Mercea, D., & Procopciuc, L. M. (2024) · Medicina · doi:10.3390/medicina60111841 · Cited by 15
“Regarding baseline characteristics, in our study that included T2DM patients with HFpEF and HFmrEF, the findings are in agreement with the results from some clinical trials, such as PARAGON-HF, PARAMOUNT and PARAGLIDE-HF, which included patients with T2DM as almost half of the samples [32–34].”
Lu, H. Y., Inciardi, R. M., Abanda, M. H., Shah, A. M., Čikeš, M., Claggett, B. L., Prasad, N., Lam, C. S. P., Redfield, M. M., McMurray, J. J. V., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037380 · Cited by 13
“12,13 The association between the number of abnormal RV parameters with other outcomes (which were time- to-first events) was analyzed using Cox proportional hazards models.”
Self-citationCurrent Treatment of Heart Failure with Preserved Ejection Fraction
Riccardi, M., D’Elia, E., Lombardi, C., Savarese, G., Gori, M., Oliva, F. G., Volterrani, M., Senni, M., Metra, M., & Inciardi, R. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155406 · Cited by 13
“In the “Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction (PARAGON-HF)” [21], the primary composite endpoint of total hospitalizations for HF and CV death was only numerically lower with sacubitril/valsartan (12.8 events per 100 patient-years vs. 14.6 events per…”
InfluentialSelf-citationHeart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
Margonato, D., Mazzetti, S., Maria, R. D., Gorini, M., Iacoviello, M., Maggioni, A. P., & Mortara, A. (2020) · Cardiac failure review · doi:10.15420/cfr.2020.13 · Cited by 13
“In the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) trial, ARNI failed to reduce the primary composite endpoint of total hospitalisations for HF and CV death in patients with HF and LVEF ≥45%.(54) However, when d…”
ResultSelf-citationCamafort, M., Adeseye, A., Coca, A., Damasceno, A. A. M., SIMONE, G. D., Dorobanţu, M., Jhund, P. S., Kario, K., Komori, T., Lee, H. Y., et al. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00446-8 · Cited by 13
Self-citationLi, W., Katamreddy, A., Kataria, R., Myerson, M. L., & Taub, C. C. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00277-0 · Cited by 13
Heart failure with preserved ejection fraction: a stepchild no more!
Braunwald, E. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab601 · Cited by 13
Xü, Y., Chen, Y., Zhao, J. W., Li, C., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.604017 · Cited by 14
“Different RAASi were used in the control group, including valsartan 320 mg daily (28.3%, 2,599/9,189, PARAMOUNT, PARAGON, and PRIME), enalapril 20 mg daily (54.4%, 4,998/ 9,189, PARADIGM, PIONEER, EVALUATE, and PARALLEL), ramipril 10 mg daily (1.1%, 100/9,189, Post-STEMI), and irbesartan 300 mg once daily (2.3%, 207/9…”
BackgroundInfluentialSavarese, G., Uijl, A., Ouwerkerk, W., Tromp, J., Anker, S. D., Dickstein, K., Hage, C., Lam, C. S. P., Lang, C. C., Metra, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13917 · Cited by 13
Self-citationCvijić, M., Rib, Y., Danojevic, S., Radulescu, C.-I., Nazghaidze, N., & Vardas, P. E. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10267-1 · Cited by 16
Song, Y., Zhao, Z., Zhang, J., Zhao, F., & Jin, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.922721 · Cited by 13
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 17
“PARAGON-HF (NCT01920711) →no significant benefit in patients with HF and preserved ejection fraction (HFpEF) regarding total hospitalizations for HF and death from cardiovascular causes [12]”
BackgroundResultDefining the Phenotypes for Heart Failure With Preserved Ejection Fraction
Rucker, D., & Joseph, J. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00582-x · Cited by 13
Wu, M., Ying, W., Chen, W., Kaizu, X., Song, M., & Lin, L. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10338-x · Cited by 14
Charkviani, M., Krisanapan, P., Thongprayoon, C., Craici, I. M., & Cheungpasitporn, W. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.008 · Cited by 14
“Despite the very low quality of evidence, our fi ndings align with the results of the PARAGON-HF trial, 37 which also failed to fi nd a signi fi cant bene fi t of sacubitril-valsartan in patients with HFpEF.”
ResultVericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial
Lang, N. N., Dobbin, S. J. H., & Petrie, M. C. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa247 · Cited by 13
Mitchell, G. F., Solomon, S. D., Shah, A. M., Claggett, B. L., Fang, J. C.-T., Izzo, J. L., Abbas, C. A., Desai, A. S., Martinez-Castrillon, M., Gables, C., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007891 · Cited by 14
Self-citationNorre, T., Grimm, D. G., & Simonsen, U. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13714 · Cited by 13
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease
Judge, P. K., & Haynes, R. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000659 · Cited by 13
Volpe, M., & Gallo, G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab489 · Cited by 13
Grant, A. D. M., Chew, D. S., Howlett, J. G., & Miller, R. J. H. (2020) · CJC Open · doi:10.1016/j.cjco.2020.05.009 · Cited by 12
Matsumoto, S., Nakamura, N., Konishi, M., Shibata, A., Kida, K., Ishii, S., Ikeda, T., & Ikari, Y. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14083 · Cited by 14
Warner, A. L., Lu, L., Ghaznavi, Z., & Jackevicius, C. A. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.008936 · Cited by 14
Butler, J., Zheng, Y., Khan, M. S., Bonderman, D., Lund, L. H., deFilippi, C. R., Blaustein, R. O., Ezekowitz, J. A., Freitas, C., Hernandez, A. F., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.12.014 · Cited by 12
Self-citationMatsumoto, S., Shen, L., Henderson, A. D., Böhm, M., Desai, A. S., Køber, L., Lefkowitz, M. P., Packer, M., Rouleau, J. L., Solomon, S. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.012 · Cited by 15
Self-citationBauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
Clinical Phenotyping and Treatment Response in Patients With Chronic Heart Failure
Tatsuta, D., Nakao, M., Nagai, T., Mizuguchi, Y., Yokota, I., Koya, T., Tada, A., Ishizaka, S., George, F., Kato, Y., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101972 · Cited by 13
Heart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Diastolic Heart Failure: A Review of Current and Future Treatment Options
Goldstein, D., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000303 · Cited by 12
Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction
Salah, H. M., Fudim, M., Alaref, S. J., Khan, M. S., Almarzooq, Z., Devabhaktuni, S. R., Mentz, R. J., Butler, J., & Greene, S. J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.01.013 · Cited by 12
Fukuta, H., Hagiwara, H., & Kamiya, T. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101103 · Cited by 16
Aging and Heart Failure with Preserved Ejection Fraction
Larson, K. F., Malik, A., & Brozovich, F. V. (2022) · Comprehensive physiology · doi:10.1002/cphy.c210035 · Cited by 12
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
Iovanovici, D. C., BUNGAU, S. G., Vesa, C. M., Moisi, M. I., Babeş, E. E., Ţiţ, D. M., Horvath, T., Behl, T., & Rus, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911336 · Cited by 14
“The results favor S/V except for hospitalizations and CV deaths, where there was no statistically significant difference [98].”
ResultElkammash, A., Tam, S. S. C., Yogarajah, G., & You, J. (2023) · Cureus · doi:10.7759/cureus.35030 · Cited by 13
“The PARAGON-HF was a large RCT that included 4822 HFpEF patients (46% aged 75 years or older).”
BackgroundInfluentialCirculating sphingolipids in heart failure
Kovilakath, A., Wohlford, G. F., & Cowart, L. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1154447 · Cited by 14
Zhang, J., Zhang, W., Yan, J., Ge, Q., Lu, X., Chen, S.-X., Xu, W., Li, Y., Li, J., He, S.-Y., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01326-7 · Cited by 14
How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?
Çelik, A., Kılıçaslan, B., Temizhan, A., Güvenç, T. S., Altay, H., Çavuşoğlu, Y., Yılmaz, M. B., Yıldırımtürk, Ö., Nalbantgil, S., & Ural, D. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.3297 · Cited by 15
Sohani, Z. N., Behlouli, H., de Moura, C. S., Abrahamowicz, M., & Pilote, L. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028865 · Cited by 12
“PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) 14 has been the only trial testing the efficacy of sacubitril– valsartan to have included an equal proportion of men and women and, interestingly, reported a statistic…”
InfluentialZhang, Z., Xiao, Y., Dai, Y., Lin, Q., & Liu, Q. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10366-7 · Cited by 14
Contemporary approach to treating heart failure
Brann, A. M., Tran, H. A., & Greenberg, B. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.011 · Cited by 15
LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials
Chen, X., Jin, C., Xie, L., & Xiang, M. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.01.2 · Cited by 13
Razavi, A. C., Potts, K. S., Kelly, T. N., He, J., Fernandez, C., Krousel-Wood, M. A., Anderson, A. H., Bundy, J. D., Whelton, S. P., Blumenthal, R. S., et al. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01485-2 · Cited by 12
Advances in the Management of Acute Decompensated Heart Failure
Mitter, S. S., & Pinney, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.002 · Cited by 16
Uijl, A., Veenis, J. F., Rocca, H. B., van Empel, V. P. M., Linssen, G. C. M., Asselbergs, F. W., van der Lee, C., Eurlings, L. W. M., Kragten, H. A., Al-Windy, N. Y. Y., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-020-01534-7 · Cited by 12
Morishita, T., Takeishi, N., Ii, S., & Wada, S. (2021) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02706-7 · Cited by 12
Sex and Heart Failure Treatment Prescription and Adherence
Farrero, M., Bellumkonda, L., Otero, I. G., & Molina, B. D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.630141 · Cited by 13
Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases
Gulsin, G. S., Graham-Brown, M. P. M., Squire, I. B., Davies, M. J., & McCann, G. P. (2021) · Heart · doi:10.1136/heartjnl-2021-319185 · Cited by 12
Galati, G., Андреевна, Г. О., Iozzo, R. V., Buraschi, S., Shchukin, Y. V., Germanov, A. V., Germanov, V. A., Терешина, О. В., Senni, M., & Margonato, A. (2021) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05786-0 · Cited by 12
Self-citationDrexel, H., Pocock, S., Lewis, B. S., Saely, C. H., Kaski, J. C., Rosano, G. M. C., Tautermann, G., Huber, K., Dopheide, J. F., MADER, A., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab048 · Cited by 12
Takami, T., Hoshide, S., & Kario, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00771-6 · Cited by 12
“However, a subgroup analysis of this study was performed to determine whether the superiority of ARNi over valsartan could be observed in patients with an EF of 57% or less [7, 62].”
BackgroundMethodResultHypertensive Heart Failure in Asia
Rismiati, H., & Lee, H. (2021) · Pulse · doi:10.1159/000518661 · Cited by 12
Does sacubitril/valsartan work in acute myocardial infarction? The PARADISE-AMI study
Gatto, L. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab098 · Cited by 12
Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
Chen, L., Huang, Z., Zhao, X., Liang, J., Lu, X., He, Y., Kang, Y. M., Xie, Y., Liu, J., Liu, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.820178 · Cited by 12
“However, reliable risk stratification systems for patients with HFpEF are still lacking, which make it difficult for physicians to intervene and treat high-risk patients (6).”
BackgroundA pilot clinical trial of cell therapy in heart failure with preserved ejection fraction
Vrtovec, B., Frljak, S., Poglajen, G., Zemljič, G., Cerar, A., Sever, M., Haddad, F., & Wu, J. C. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2596 · Cited by 12
Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
Formiga, F., Chivite, D., Núñez, J. E., García, M. C. M., Manzano, L., Arévalo‐Lorido, J. C., Cerqueiro, J. M., Campos, Á. G., Trullàs, J. C., & Montero-Pérez-Barquero, M. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.06.027 · Cited by 12
Mahtani, K., Patel, B., Wang, B., & Barron, A. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.08.015 · Cited by 12
Recent advances in the treatment of chronic heart failure
Buckley, L. F., & Shah, A. M. (2019) · F1000Research · doi:10.12688/f1000research.20447.1 · Cited by 15
Butt, J. H., Jering, K., de Boer, R. A., Claggett, B. L., Desai, A. S., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Køber, L., Kosiborod, M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.08.027 · Cited by 11
“Compared with patients with HFrEF, those with HFpEF are typically older, more obese and more commonly have atrial fi brillation, 27,28,41,42 all of which are strongly associated with sleep-disordered breathing.”
BackgroundSelf-citationEpicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Dhore-Patil, A., Urina‐Jassir, D., Samson, R., Jemtel, T. H. L., & Oparil, S. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01302-7 · Cited by 13
“Cardiovascular mortality was 8.9% over 35 months in the placebo arm of the sacubitril/valsartan HFpEF trial [69].”
BackgroundInfluentialDixit, N. M., Truong, K. P., Vaduganathan, M., Ziaeian, B., & Fonarow, G. C. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.03.006 · Cited by 12
Beta blockers are associated with lower all-cause mortality among HFpEF patients
Ibrahim, J., Fabrizio, C. A., Sezer, A., Thoma, F. W., Boyle, B., Mulukutla, S. R., Huston, J., Simon, M. A. M., & Hickey, G. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02451-0 · Cited by 12
“Various RCTs, including PEP-CHF (perindopril) [8], I-PRESERVE (irbesartan) [9], TOPCAT (spironol-actone) [10], PARAGON-HF (sacubitril/valsartan) [11], and CHARM-PRESERVED (Candesartan) [12], were conducted in HFpEF patients and failed to reach their primary mortality endpoints.”
Geschlechterspezifische Aspekte kardiovaskulärer Erkrankungen
Baessler, A., Bauer, P., Becker, M., Berrisch-Rahmel, S., Goldmann, B. U., Grünig, E., Hamm, C., Meder, B., Kindermann, I., Ong, P., et al. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00694-9 · Cited by 11
Chattranukulchai, P., Roubsanthisuk, W., Kunanon, S., Kotruchin, P., Satirapoj, B., Wongpraparut, N., Sunthornyothin, S., & Sukonthasarn, A. (2024) · Hypertension Research · doi:10.1038/s41440-024-01785-6 · Cited by 15
Yang, M., Kondo, T., Anand, I. S., de Boer, R. A., Campbell, R. T., Køber, L., Lam, C. S. P., Maggioni, A. P., Martínez, F. A., O’Meara, E., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3417 · Cited by 11
Self-citationSacubitril/Valsartan vs ACE Inhibitors or ARBs
Evbayekha, E. O., Idowu, A. B., & LaRue, S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101598 · Cited by 11
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model
McDowell, K., Docherty, K. F., Campbell, R. T., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Hofmeister, L. H., Scalise, A. V., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0025 · Cited by 11
Self-citationNoiri, J., Fujimoto, W., Takemoto, M., Kuroda, K., Yamashita, S., Imanishi, J., Iwasaki, M., Todoroki, T., Okuda, M., Nagao, M., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0002 · Cited by 11
Ozaki, Y., Uemura, Y., Kondo, T., Kazama, S., Yamaguchi, S., Okajima, T., Mitsuda, T., Ishikawa, S., Takemoto, K., Okumura, T., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0092 · Cited by 11
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Neuen, B. L., Beldhuis, I. E., Butt, J. H., Biering‐Sørensen, T., Desai, A. S., Lewis, E. F., Jhund, P. S., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.042 · Cited by 11
Self-citationPediatric heart failure: Current approach and treatment
Olsen, B. A., & Miyamoto, S. D. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100331 · Cited by 11
Borlaug, B. A., Zile, M. R., Kramer, C. M., Litwin, S. E., Ye, W., Ou, Y., Hurt, K. C., Murakami, M., & Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf663 · Cited by 11
Self-citationAficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Masri, A., Maron, M. S., Bhatia, A., Peña‐Peña, M. L., Sherrid, M. V., Figueiredo, E. L., Arad, M., Barriales-Villa, R., Choudhury, L., Claggett, B. L., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603021 · Cited by 14
Self-citationUnderstanding the Results of the PARAGON-HF Trial
Ferrari, R., Fucili, A., & Rapezzi, C. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1797 · Cited by 11
Nakagawa, A., Yasumura, Y., Yoshida, C., Okumura, T., Tateishi, J., Yoshida, J., Tamaki, S., Yano, M., Hayashi, T., Nakagawa, Y., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02098-z · Cited by 11
Capric, V., Chandrakumar, H. P., Celenza-Salvatore, J., & Makaryus, A. N. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96415 · Cited by 11
Utilization and tolerance of beta-blockers among patients with AL amyloidosis
Briasoulis, Α., Stamatelopoulos, K. S., Petropoulos, Ι., Patras, R., Theodorakakou, F., Gavriatopoulou, M., Ntalianis, A., Dimopoulos, M. A., & Kastritis, E. (2021) · Amyloid · doi:10.1080/13506129.2021.1981281 · Cited by 11
Lin, Y., Wu, M., Liao, B., Pang, X., Chen, Q., Yuan, J., & Dong, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.707777 · Cited by 12
“It should also be noted that the patients of the included RCTs may not represent the real-life situation by the intrinsic selective bias such as enrolled patients being relatively younger and having fewer comorbidities.”
BackgroundInfluentialBell, S. P., & Rich, M. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_19 · Cited by 11
Larina, V. N., Skiba, I. K., & Skiba, A. S. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4820 · Cited by 11
Evaristi, M. F., Poirier, B., Chénedé, X., Lefebvre, A., Roccon, A., Gillot, F., Beeské, S., Corbier, A., Pruniaux-Harnist, M.-P., Janiak, P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0257929 · Cited by 11
“Multiple clinical trials have investigated approved drugs in heart failure with reduced ejection fraction in the context of HFpEF with disappointing results [3, 4].”
BackgroundSacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
Muric, M. D., Srejovic, I. M., Joksimović, J., Sretenovic, J. Z., Jeremic, J. N., Čekerevac, I., Simovic, S. M., Djoković, D., Muric, N. N., Stojić, V., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2307238 · Cited by 13
“S/V showed no significant benefit over valsartan in reducing composite outcome of total HF hospitalizations and CV death [55].”
BackgroundMethodPharmacologic Therapy for Heart Failure with Preserved Ejection Fraction
Peters, A. E., & DeVore, A. D. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2022.06.004 · Cited by 11
Sakaguchi, E., Yamada, A., Naruse, H., Hattori, H., Nishimura, H., Kawai, H., Muramatsu, T., Ishii, J., Hata, T., Saito, K., et al. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02211-y · Cited by 12
Bayesian Inference for a Principal Stratum Estimand on Recurrent Events Truncated by Death
Lyu, T., Bornkamp, B., Mueller‐Velten, G., & Schmidli, H. (2023) · Biometrics · doi:10.1111/biom.13831 · Cited by 11
“The results for 𝑡 ∗ = 1 show an estimated RR (95% CI) of 0.773 (0.639, 0.933), which reflects the treatment effect on hospitalizations within one year in a subpopulation that would be still alive at one year and thus likely somewhat healthier and less frail than the population randomized to PARAGON-HF, as about 7% of…”
MethodInfluentialLee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
“In PARAGON-HF, sacubitril/valsartan was associated with a 13% non-significant reduction in the composite of total hospitalization for HF and CV death in HF with an LVEF ≥45%; among subgroups, the benefit was greater in women and those with LVEF ≤57%.(64) The US Food and Drug Administration (FDA) have granted sacubitri…”
BackgroundPredicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
Kondo, T., Jering, K., Jhund, P. S., Anand, I. S., Desai, A. S., Lam, C. S. P., Maggioni, A. P., Martínez, F. A., Packer, M., Petrie, M. C., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010377 · Cited by 14
Self-citationObesity-Related Differences in Pathomechanism and Outcomes in Patients With HFpEF
Nakamori, S., Kucukseymen, S., Rodriguez, J., Yazdanian, F., Ngo, L. H., Gopal, D. M., Manning, W. J., & Nezafat, R. (2023) · JACC: Advances · doi:10.1016/j.jacadv.2023.100730 · Cited by 11
Latest pharmaceutical approaches across the spectrum of heart failure
Bismpos, D., Wintrich, J., Hoevelmann, J., & Böhm, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10389-8 · Cited by 11
“Furthermore, when examining the subgroup of patients with EF between 45 and 57%, a significant benefit was suggested [26].”
BackgroundKommu, S., & Berg, R. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061572 · Cited by 14
“Conversely, the PARAGON-HF trial by Solomon et al. reported that sacubitril/valsartan did not significantly lower the rate of total hospitalizations for HF and cardiovascular death among patients with HF and an ejection fraction of 45% or higher [11].”
BackgroundMethodResultInfluentialAn Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S. A., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 13
“…Sacubi-tril/valsartan vs valsartan in 4822 patients with HFpEF, and found reduced rates of the composite primary outcome of total hospitalisations for HF and death from cardiovascular causes (rate ratio 0.87), albeit this narrowly missed statistical significance (95% CI 0.75–1.01; p = 0.06) [29].”
BackgroundResultInfluentialHammersley, D. J., Mukhopadhyay, S., Chen, X., Jones, R. E., Ragavan, A., Javed, S., Rajabali, H., Androulakis, E. S., Curran, L., Mach, L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3425 · Cited by 11
“16,17 Many patients with DCMmrEF however do not have symptoms (including 57% of this cohort), and may have normal natriuretic peptides.”
BackgroundEffects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure
Lu, H. Y., Claggett, B. L., Packer, M., Lam, C. S. P., Swedberg, K. B., Rouleau, J. L., Zile, M. R., Lefkowitz, M. P., Desai, A. S., Jhund, P. S., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.2566 · Cited by 11
Self-citationAbdulsalam, T. M., Hasanin, A. H., Mohamed, R. H., & Badawy, A. E. S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173295 · Cited by 11
Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence
Koufou, E., Arfaras-Melainis, A., Rawal, S., & Kalogeropoulos, A. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020203 · Cited by 11
“Sacubitril/valsartan did not significantly lower the composite of total hospitalizations for HF and death from cardiovascular causes, despite modest improvements in NYHA class and less decline in renal function [31].”
BackgroundMethod
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.